Basic Genomics

Executive Summary

Basic Genomics is a Swedish biotechnology company founded in 2015 that has developed the RNA BaseCode™ platform, a proprietary technology that converts standard short-read RNA sequencing data into high-accuracy synthetic long reads. This enables full-length isoform analysis, providing deeper insights into gene regulation and disease mechanisms. The company aims to democratize complex RNA biology by making its platform accessible to every lab. Despite being privately held with no disclosed funding or valuation, Basic Genomics holds potential to disrupt the transcriptomics market by addressing the limitations of short-read sequencing. The company's focus on RNA isoform resolution aligns with growing demand for precision medicine and biomarker discovery. However, as a private entity with limited public information, its near-term trajectory remains uncertain, though its technology could attract strategic partnerships or investment as the field advances.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of RNA BaseCode platform or beta program30% success
• Q1 2027Strategic partnership with major sequencing or pharma company25% success
• Q2 2026Publication of key validation data in peer-reviewed journal50% success